These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33095662)

  • 21. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO
    Wedzicha JA; Buhl R; Singh D; Vogelmeier CF; de la Hoz A; Xue W; Anzueto A; Calverley PMA
    Adv Ther; 2020 Oct; 37(10):4266-4279. PubMed ID: 32776202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.
    Maltais F; Hamilton A; Voß F; Maleki-Yazdi MR
    Adv Ther; 2019 Apr; 36(4):962-968. PubMed ID: 30843141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
    Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
    Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study Design of VESUTO
    Ichinose M; Minakata Y; Motegi T; Ueki J; Seki T; Anzai T; Takizawa A; Grönke L; Hirata K
    Adv Ther; 2017 Jul; 34(7):1622-1635. PubMed ID: 28537001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.
    Ferguson GT; Buhl R; Bothner U; Hoz A; Voß F; Anzueto A; Calverley PMA
    Respir Med; 2018 Oct; 143():67-73. PubMed ID: 30261995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD.
    Andreas S; McGarvey L; Bothner U; Trampisch M; de la Hoz A; Fležar M; Buhl R; Alter P
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1935-1944. PubMed ID: 32848379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
    Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L
    Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease.
    Takahashi K; Tashiro H; Tajiri R; Takamori A; Uchida M; Kato G; Kurihara Y; Sadamatsu H; Kinoshita T; Yoshida M; Kawaguchi A; Kimura S; Sueoka-Aragane N; Kawayama T;
    Int J Chron Obstruct Pulmon Dis; 2021; 16():3297-3307. PubMed ID: 34908832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of chronic obstructive pulmonary disease (COPD) treatment with a combination of tiotropium / olodaterol in Polish standard clinical practice as measured by the improvement of the Clinical COPD Questionnaire score: an observational study.
    Kania A; Celejewska-Wójcik N; Żurowska K; Barczyk A
    Pol Arch Intern Med; 2022 Aug; 132(7-8):. PubMed ID: 35635728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
    Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
    Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review.
    Melani AS
    Expert Opin Pharmacother; 2018 Oct; 19(14):1603-1611. PubMed ID: 30311516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
    Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
    Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tiotropium/Olodaterol: A Review in COPD.
    Blair HA
    Drugs; 2019 Jun; 79(9):997-1008. PubMed ID: 31119643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
    Miravitlles M; Urrutia G; Mathioudakis AG; Ancochea J
    Respir Res; 2017 Nov; 18(1):196. PubMed ID: 29178871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD.
    Pelaia G; Vatrella A; Busceti MT; Gallelli L; Calabrese C; Terracciano R; Lombardo N; Maselli R
    Ther Clin Risk Manag; 2015; 11():1563-72. PubMed ID: 26504398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients.
    Valipour A; Tamm M; Kociánová J; Bayer V; Sanzharovskaya M; Medvedchikov A; Haaksma-Herczegh M; Mucsi J; Fridlender Z; Toma C; Belevskiy A; Matula B; Šorli J
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2343-2354. PubMed ID: 31632003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.